Major Manufacturing Milestones Achieved
Structural assembly of all three major ship components (wing, fuselage, feather) is complete or near completion; joining of subassemblies underway with weight-on-wheels expected in weeks and ground testing (PAT/IVGT) starting in April 2026. Final assembly time materially shortened, enabling faster repeatable production.
Clear Flight Test and Commercial Timeline
Flight-test program on track: glide and rocket-powered tests planned in Q3–Q4 2026, with first commercial spaceflight targeted for Q4 2026. Ramp plan: ~4 flights/month initially, then ~8/month, with a goal of 10+ flights/month in 2027 (subject to vehicle and operational readiness).
Sales Reopened with Premium Pricing
Opened a limited tranche of 50 spaceflight expeditions priced at $750,000 per seat; website and sales infrastructure relaunched. Founding astronaut community exceeds ~650 members; additional limited premium opportunities for being among first 1,000 humans in space priced substantially higher.
Launch Vehicle and Capacity Improvements
Mothership 'Eve' received upgrades targeting launch-support capacity of up to 12–15 spaceflights/month (providing buffer for weather-related delays). LVX launch vehicle program progressing, targeting deployment with additional spaceships in 2030 to expand capacity beyond Eve.
Capital Realignment Reduced Near-Term Debt Burden
December exchange addressed $355M of the $425M 2027 convertibles, extending maturity to December 2028, and eliminated $142M of contractual debt payments. Warrants issued with exercise price >2x recent stock price, offering upside-aligned potential and cash inflows on exercise.
Reduced Operating Costs and Improving Profitability Trends
Q4 operating expenses down 26% YoY to $61M (from $82M); Q4 net loss improved 18% YoY to $63M (from $76M); adjusted EBITDA improved 23% YoY to -$49M (from -$63M). FY2025 operating expenses down 25% YoY to $287M; net loss improved 20% YoY to $279M; adjusted EBITDA improved 22% YoY to -$226M.
Balance Sheet and CapEx Investments Supporting Scale
Year-end cash, cash equivalents, and marketable securities of $338M; $122M gross proceeds raised via ATM in 2025. Capital expenditures $198M in 2025 (up from $122M), PP&E increased 86% YoY to $389M, reflecting investments in production capacity and tooling expected to enable scalable manufacturing.